<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04999592</url>
  </required_header>
  <id_info>
    <org_study_id>1P20GM139745-01</org_study_id>
    <nct_id>NCT04999592</nct_id>
  </id_info>
  <brief_title>Ceftriaxone to PRevent pneumOnia and inflammatTion aftEr Cardiac arresT (PROTECT)</brief_title>
  <acronym>PROTECT</acronym>
  <official_title>Ceftriaxone to PRevent pneumOnia and inflammatTion aftEr Cardiac arresT (PROTECT): a Randomized-controlled Trial and Microbiome Assessment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David J. Gagnon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MaineHealth</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of New England</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MaineHealth</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized-controlled trial and microbiome assessment to understand the risk-to-benefit ratio&#xD;
      of prophylactic antibiotics (Ceftriaxone) vs placebo in patients with pneumonia and&#xD;
      inflammation after cardiac arrest outside the hospital.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pneumonia is an infection of the lungs resulting in alveolar inflammation and fluid or&#xD;
      purulent material accumulation. It is the most common infection after cardiac arrest&#xD;
      occurring in up to 65% of patients treated with targeted temperature management. Pneumonia&#xD;
      may result from aspiration during cardiopulmonary resuscitation (CPR), or by introduction of&#xD;
      oropharyngeal flora into the lungs during airway management. Preventing infection after OHCA&#xD;
      may: 1) reduce exposure to broad-spectrum antibiotics and subsequent collateral damage, 2)&#xD;
      prevent hemodynamic derangements due to local and systemic inflammation, and 3) prevent an&#xD;
      association between infection and morbidity and mortality. These benefits must be balanced&#xD;
      with the risk for altering bacterial resistomes in the absence clinical infection.&#xD;
      Accordingly, further study is warranted to understand the risk-to-benefit ratio of&#xD;
      prophylactic antibiotics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The clinical team responsible for the participant (physicians, nurses and others) and involved with direct patient care will be blinded. Investigators will be blinded and the placebo will match the study drug. Outcomes Assessors will be blinded to treatment assignment during assessments of pneumonia and functional outcome.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Clinically-diagnosed Early-onset Pneumonia</measure>
    <time_frame>4 days</time_frame>
    <description>Percentage of Participants with Clinically-diagnosed Early-onset Pneumonia occurring &lt;4 days after initiation of mechanical ventilation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Microbiologically-confirmed Early-onset Pneumonia</measure>
    <time_frame>4 days</time_frame>
    <description>Percentage of Participants with Microbiologically-confirmed Early-onset Pneumonia occurring &lt;4 days after initiation of mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Microbiologically-confirmed late-onset pneumonia</measure>
    <time_frame>≥ 4 days</time_frame>
    <description>Percentage of Participants with Microbiologically-confirmed late-onset pneumonia occurring ≥4 days after initiation of mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Clinically-diagnosed late-onset pneumonia</measure>
    <time_frame>≥ 4 days</time_frame>
    <description>Percentage of Participants with Clinically-diagnosed late-onset pneumonia occurring ≥4 days after initiation of mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with non-pulmonary infections</measure>
    <time_frame>During the intervention and immediately after the intervention until hospital discharge, up to 6 months</time_frame>
    <description>Percentage of Participants with non-pulmonary infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU-free days during admission</measure>
    <time_frame>28 days</time_frame>
    <description>ICU-free days in the first 28 days of admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilator-free days during admission</measure>
    <time_frame>28 days</time_frame>
    <description>Mechanical ventilator-free days in the first 28 days of admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU Length of Stay</measure>
    <time_frame>During the intervention and immediately after the intervention until death or ICU discharge measured in days, up to 6 months</time_frame>
    <description>Intensive care unit length of stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of Stay</measure>
    <time_frame>During the intervention and immediately after the intervention until death or hospital discharge measured in days, up to 6 months</time_frame>
    <description>hospital length of stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who die in the intensive care unit</measure>
    <time_frame>During the intervention and immediately after the intervention until death or ICU discharge</time_frame>
    <description>Percentage of Participants who die in the intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Die in the Hospital</measure>
    <time_frame>During the intervention and immediately after the intervention until death or hospital discharge</time_frame>
    <description>Percentage of Participants who Die in the Hospital during admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Discharged Home or to Rehabilitation</measure>
    <time_frame>During the intervention and immediately after the intervention until death or hospital discharge</time_frame>
    <description>Percentage of Participants Discharged Home or to Rehabilitation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Transferred to Another Hospital</measure>
    <time_frame>During the intervention and immediately after the intervention until death or hospital transfer</time_frame>
    <description>Percentage of Participants Transferred to Another Hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with a Good Functional Outcome at Hospital Discharge</measure>
    <time_frame>After the intervention at the time the participant is discharged from the hospital</time_frame>
    <description>Percentage of Participants with a Good Functional Outcome at Hospital Discharge Good functional outcome will be mRS ≤0-3 of or a CPC 1-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>13. Percentage of Participants with a Good Functional Outcome at 6 Months Post-hospital Discharge</measure>
    <time_frame>6 months post-hospital discharge</time_frame>
    <description>13. Percentage of Participants with a Good Functional Outcome at 6 Months Post-hospital Discharge. Good functional outcome will be mRS ≤0-3 of or a CPC 1-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Clostridioides difficile-associated Diarrhea</measure>
    <time_frame>During the intervention and immediately after the intervention until death or hospital discharge</time_frame>
    <description>Percentage of Participants with Clostridioides difficile-associated Diarrhea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Type One Hypersensitivity Reactions</measure>
    <time_frame>Three days</time_frame>
    <description>Percentage of Participants with Type One (immediate-type) hypersensitivity reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Gallbladder disease</measure>
    <time_frame>During the intervention and immediately after the intervention until death or hospital discharge</time_frame>
    <description>Percentage of Participants with Gallbladder disease</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Out-Of-Hospital Cardiac Arrest</condition>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>No prophylaxis (placebo)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard care without antibiotic prophylaxis and treatment of infection if clinically warranted.&#xD;
Administer antibiotics in response to infection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antibiotic prophylaxis for 3 days. Antibiotic prophylaxis with Ceftriaxone 2 gm IV q12h for 3 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of care without prophylaxis</intervention_name>
    <description>Administer antibiotics in response to infection</description>
    <arm_group_label>No prophylaxis (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotic prophylaxis</intervention_name>
    <description>Ceftriaxone 2 gm IV q12h for 3 days</description>
    <arm_group_label>Prophylaxis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥18 years of age&#xD;
&#xD;
          -  Comatose (do not follow simple verbal commands)&#xD;
&#xD;
          -  Have any initial heart rhythm (shockable or non-shockable)&#xD;
&#xD;
          -  OHCA including the emergency department&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Name on opt-out list&#xD;
&#xD;
          -  In-hospital cardiac arrest&#xD;
&#xD;
          -  Interval &gt;6 hours from ICU admission to study drug receipt&#xD;
&#xD;
          -  Preexisting terminal disease making 180-day survival unlikely&#xD;
&#xD;
          -  Refused informed consent&#xD;
&#xD;
          -  Emergent coronary artery bypass grafting&#xD;
&#xD;
          -  Anaphylaxis or angioedema to beta-lactam antibiotics (i.e., cephalosporins or&#xD;
             penicillins)&#xD;
&#xD;
          -  Under legal guardianship or prisoner&#xD;
&#xD;
          -  Known colonization with methicillin-resistant Staphylococcus aureus (MRSA) or&#xD;
             vancomycin-resistant enterococcus (VRE)&#xD;
&#xD;
          -  Clinical bacterial infection prior to hospital admission defined as any one of the&#xD;
             following:&#xD;
&#xD;
               -  Infectious prodrome preceding OHCA&#xD;
&#xD;
               -  Active course of antibiotics for infection prior to admission&#xD;
&#xD;
               -  Active infection documented in the electronic medical record&#xD;
&#xD;
               -  Family or surrogate endorsement of an active infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David Gagnon, PharmD</last_name>
    <phone>207-662-1338</phone>
    <email>dgagnon@mmc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine Lord, BSN, RN</last_name>
    <phone>207-662-5432</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Gagnon, PharmD</last_name>
      <phone>207-662-1338</phone>
      <email>Dgagnon@mmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Christine Lord, BSN, RN</last_name>
      <phone>207-662-5432</phone>
      <email>LordC@mmc.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 8, 2021</study_first_submitted>
  <study_first_submitted_qc>August 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>MaineHealth</investigator_affiliation>
    <investigator_full_name>David J. Gagnon</investigator_full_name>
    <investigator_title>Critical Care Clinical Pharmacist</investigator_title>
  </responsible_party>
  <keyword>out-of-hospital cardiac arrest</keyword>
  <keyword>cardiac arrest</keyword>
  <keyword>pneumonia</keyword>
  <keyword>randomized clinical trial</keyword>
  <keyword>infection</keyword>
  <keyword>ceftriaxone</keyword>
  <keyword>microbiome</keyword>
  <keyword>inflammation</keyword>
  <keyword>prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Out-of-Hospital Cardiac Arrest</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

